Form 4: Director Michael Holder Receives MDxHealth Stock Options

Director Michael Holder was granted 10,000 stock options in MDxHealth SA as part of a standard equity compensation arrangement.

Summary

• Director Michael Holder received a grant of 10,000 share options on June 1, 2026.
• The options have an exercise price of $0.76 per share.
• The options are set to expire on May 28, 2036.
• The grant vests in full on the date of the annual general shareholders' meeting in 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial position.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Minor dilution potential for existing shareholders upon future exercise of options.

Risks

• Market price volatility may impact the future value of the granted options.
• Vesting is contingent upon the director remaining with the company until the 2027 annual general meeting.

Future Outlook

The options vest in full at the 2027 annual general shareholders' meeting, indicating a long-term retention incentive for the director.

Industry Context

StockSavvy.ai notes that equity grants to non-executive directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard director compensation packages for small-cap healthcare and diagnostic companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution impact upon exercise.
• Director: Increased alignment with company performance.

Next Steps

• Vesting of options at the 2027 annual general shareholders' meeting.

Key Dates

Keywords

MDxHealth, MDXH, Director Compensation, Stock Options, Insider Trading, Form 4